logo
Mr Samed Agirbas President of the Zero Waste Foundation on International Zero Waste Day

Mr Samed Agirbas President of the Zero Waste Foundation on International Zero Waste Day

Community Action needed to tackle global waste challenge
ISTAMBUL, TURKEY, March 30, 2025 / EINPresswire.com / -- On International Zero Waste Day, the global waste challenge has reached unsustainable proportions. According to the United Nations, the world generates between 2.1 billion and 2.3 billion tonnes of municipal solid waste every year. The global direct cost of managing this waste is a staggering USD 252 billion. The indirect cost resulting from pollution and poor waste management is USD 361 billion. By 2050, it is estimated that most cities will run out of landfills and the direct cost of waste management globally will reach over USD 500 billion annually.
Some 2.7 billion people lack access to solid waste collecting leading to open dumping and environmental risks. In fact, waste pollution impacts human health, strains economies and leads to biodiversity loss and pollution. Supporting the United Nations Secretary-General's Advisory Group on Zero Waste, the Foundation is galvanising global support and establishing a network of like-minded governments and cities to adopt Zero Waste practices.
In the case of Turkiye, we generate more than 30 million tons of municipal solid waste every year. This is equivalent to about 400 kg per person. Whilst the Zero Waste Movement started in Turkiye, critical challenges remain. The waste collection rate in the country is 77% and the country has very sound policies. However, the illegal dumping of waste material remains a major challenge.
In 2022, H.E. Mme Emine Erdogan, the First Lady of Turkiye, and UN Secretary-General Antonio Gutteres signed the Global Zero Waste Goodwill Declaration. The initiative has since grown into an international movement involving over 62 countries with 10,000 signature of prominent persons.
What we need is stronger collective action at the local level to deal with waste management challenges. The Zero Waste Foundation, which was established to advocate for an all of society approach starting from individual responsibility and action, have established strategic partnerships in all regions of the world.
Through our partnership with Kuala Lumpur, for example, we are fostering knowledge exchange and capacity building between Turkiye and Malaysia. We support Kuala Lumpur City' Hall's Zero Waste initiative that aims to reduce the city's waste footprint from an estimated 1.4 million tonnes to 563 thousand tonnes per-year by 2040.
Other than food waste, another major source of pollution is textile and fashion. According to the United Nations, the world produces 92 million tonnes of textile waste. This means a lorry load of clothing is incinerated every second. Taking into account the tremendous pressure of the fashion and textile industry, particularly its advertising and branding machinery, the United Nations decided to focus on the theme of Textile and Fashion Waste this year.
At the Zero Waste Foundation, we call upon the fashion and textile industry to adopt sustainable policies to ensure the durability and quality of products. It goes beyond corporate social responsibility and makes good business sense to invest in the long term resilience of local communities particularly indigenous communities so that we can support circular economy practices. Only then will fashion be truly fashionable.
About Zero Waste Foundation
The Zero Waste Foundation was established in 2023 under the auspices of Emine Erdoğan, the wife of the President of Turkey, Recep Tayyip Erdoğan. The foundation operates with the aim of promoting the Zero Waste Project and ensuring its sustainability. It strives to foster an environmentally conscious society by encouraging individuals and institutions to embrace the zero-waste philosophy.
The foundation's primary objectives include raising awareness about zero waste, encouraging the exchange of knowledge and experience, and developing and disseminating best practices in this field. To achieve these goals, the foundation conducts extensive activities in areas such as education, research, project development, and implementation.
To ensure the adoption of zero-waste practices in all areas, the foundation collaborates with public institutions, the private sector, and non-governmental organizations. Additionally, it aims to create a global impact by promoting zero-waste initiatives at the international level.
https://sifiratikvakfi.org/en/about-us)
About Samed Agirbas
Samed Ağırbaş was born in 1994 in the Fatih district of Istanbul. He completed his master's degree in Business Administration and Finance at Mississippi State University. He is currently continuing his doctoral studies at the University of Massachusetts.
Ağırbaş, who was elected as the President of the Istanbul Metropolitan Municipality Youth Assembly in 2014, also assumed the roles of President of the Union of Turkish Municipalities Youth Assembly and the World Humanitarian Summit Youth Working Group. He was Special Advisor to the Executive Director of the United Nations Human Settlements Program (UN-HABITAT) and UN-HABITAT Eastern Europe and Central Asia Advisor, Ağırbaş ensured coordination of relations between UN member countries and UN agencies during his term and also led various projects. He continues his active duty at the United Nations.
Currently acting as the Chairman of the Board of Trustees and Board of Directors of the Zero Waste Foundation, Ağırbaş, who acts with the desire to be a visionary at national and international levels with sustainability, environment and youth works, speaks advanced level English and beginner level Portuguese.
Zero Waste Foundation
+60 16-460 5617
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Xsolla Relaunches UPI and Net Banking in India to Help Developers Tap Into One of the World's Fastest-Growing Gaming Markets
Xsolla Relaunches UPI and Net Banking in India to Help Developers Tap Into One of the World's Fastest-Growing Gaming Markets

Business Wire

timean hour ago

  • Business Wire

Xsolla Relaunches UPI and Net Banking in India to Help Developers Tap Into One of the World's Fastest-Growing Gaming Markets

LOS ANGELES--(BUSINESS WIRE)--Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today the relaunch of its payment offerings in India, reintroducing support for Unified Payments Interface (UPI) and Net Banking through Xsolla Pay Station. With these popular local methods, developers and publishers can deliver frictionless, culturally relevant checkout experiences that align with how Indian players prefer to pay. India is one of the most dynamic and fastest-growing gaming markets globally. With over 500 million gamers, the majority (90%) of whom are on mobile devices, and a gaming industry expected to surpass USD 4 billion in revenue by 2025, India presents a high-growth opportunity for developers looking to expand their reach. Fueled by affordable data, widespread smartphone access, and increasing investments in esports and creator-driven content, India presents a high-growth opportunity for developers. Equally impressive is India's digital payments ecosystem. In 2024, UPI facilitated more than 130 billion transactions with a total value of approximately $2.5 trillion during FY 2023-24, now accounting for over 83% of the country's digital payments. Net Banking also remains widely used, especially among urban and Tier 2/3 audiences who expect QR codes, real-time transactions, and low-friction experiences. With this relaunch, Xsolla Pay Station now supports: Unified Payments Interface (UPI) – Developed by the National Payments Corporation of India, it is the country's homegrown digital payment system. Seamlessly integrated into everyday life, it empowers over 400 million users to send and receive money instantly and securely, whether through QR code scanning, direct app-based payments, or instant bank transfers. Net Banking is a secure and trusted digital payment method that enables users to make direct transactions from their bank accounts across leading financial institutions. Regulated by the Reserve Bank of India and widely supported by major banks, it served over 300 million active users and facilitated transactions worth more than ₹93 trillion in FY 2023-24. Key benefits of the India payments relaunch include: Trusted Local Payment Methods: Support for UPI and Net Banking, aligned with India's dominant payment behaviors. Expanded Reach in a High-Growth Market: Access over 500 million Indian gamers through localized payment infrastructure. Improved Conversion Rates: You reduce friction and abandonment by offering familiar, fast payment options. Mobile-Optimized Checkout: Designed for India's smartphone-first audience, with fast, low-latency flows. Player Trust and Retention: Strengthen engagement with culturally relevant payment experiences that build confidence and loyalty. 'As the gaming economy in India accelerates, so does the need for localized payments that reflect how players live and pay,' said Chris Hewish, President at Xsolla. 'With UPI and Net Banking reintroduced through Xsolla Pay Station, we're giving developers the tools to reach more players, convert more sales, and deliver experiences native to Indian gamers.' To enable payments in India or learn more about Xsolla Pay Station, get started: For a complete list of enhancements and developer tools, visit: About Xsolla Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game. For more information, visit

Bitcoin price hits record high above $123,500 amid crypto rally
Bitcoin price hits record high above $123,500 amid crypto rally

Yahoo

time2 hours ago

  • Yahoo

Bitcoin price hits record high above $123,500 amid crypto rally

Bitcoin (BTC-USD) surged to a new all-time high above $123,500 (£90,984) in early Thursday trading, extending a week-long rally that has lifted the broader cryptocurrency market. Bitcoin briefly traded at $123,512 before easing back to around $121,700. The world's biggest cryptocurrency is now up more than 6% over the past week, breaking through its previous July peak of just over $120,000. Read more: Crypto live prices 'Bitcoin's latest rally reflects the blurring lines between crypto and traditional assets, happening faster than institutional adoption timelines predicted,' VOOI CEO and co-founder Will K said. 'While ETFs brought institutions into bitcoin, retail traders are returning to evolved decentralised platforms that have shed their clunky origins.' Ethereum (ETH-USD) outpaced bitcoin in percentage gains, jumping 28% over the past seven days to trade above $4,742, inching closer to its November 2021 record of $4,865. 'Ethereum's rally is being driven by strong ETF inflows, institutional accumulation, and a favourable macro backdrop after softer CPI data boosted rate-cut expectations,' Bitfinex head of derivatives Jag Kooner said. 'Traders have rotated back into risk, with bitcoin and ether both seeing renewed long positioning, while options data shows low implied volatility and a build-up in open interest, signalling that markets expect a sharp move ahead but are hedging downside risk.' The total cryptocurrency market capitalisation now stands at $4.23tn, up 1.9% on Thursday, according to CoinMarketCap data. The crypto rally comes as US equities closed higher on Wednesday, with the S&P 500 (^GSPC) and Nasdaq (^IXIC) hitting fresh record highs this week. The broader risk-on sentiment has spilled over into digital assets. Read more: One US law reshaped crypto overnight. Ripple explains why Bitcoin's surge has been underpinned by a friendlier regulatory climate in Washington. Earlier this month, US president Donald Trump signed an executive order directing federal banking regulators to scrap 'reputational risk' as a factor in supervision, a designation that had often led banks to cut ties with lawful crypto firms. The move, part of a broader rollback of restrictions critics dubbed 'Operation Choke Point 2.0,' has been coupled with the disbanding of the Justice Department's National Crypto Enforcement Team and new legislation to establish a federal framework for stablecoins. Industry leaders have said the shift is clearing a path for greater institutional participation in digital assets, adding momentum to bitcoin's rally. Read more: Why pension funds are buying bitcoin What is a spot bitcoin ETF and why has it sparked a crypto rally? How AI could change the internet

Kuros Biosciences Reports First Half of 2025 Results
Kuros Biosciences Reports First Half of 2025 Results

Yahoo

time5 hours ago

  • Yahoo

Kuros Biosciences Reports First Half of 2025 Results

Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million) The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024 Total Group EBITDA reached USD 5.1 million in H1 2025 (H1 2024: USD 0.8 million) and total Group adjusted EBITDA* amounted to USD 7.8 million in H1 2025, equaling a margin of 12.3% (H1 2024: USD 4.5 million at 12.6%). After amortization, depreciation, the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million) Cash position remains strong while funding strategic growth initiatives and investing in working capital, with cash and cash equivalents totaling USD 18.4 million as of June 30, 2025 (December 31, 2024: USD 19.8 million) Reporting currency changed from CHF to USD to align with the Group's primary market and operational footprint in the U.S. The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. Revenue from Direct MagnetOs product sales increased 77% year-on-year to USD 62.7 million (H1 2024: USD 35.4 million). The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an operating loss of USD (0.2) million in H1 2024. The Group achieved an EBITDA of USD 5.1 million in H1 2025, increasing from USD 0.8 million in H1 2024. Adjusted EBITDA* totaled at USD 7.8 million, up from USD 4.5 million in H1 2024. This represents an adjusted EBITDA* margin of 12.3%. The Group does not expect a material impact from U.S. tariffs in 2025. Finally, the reporting currency was changed from Swiss francs (CHF) to U.S. dollars (USD) to reflect the Group's primary market and business activities. Chris Fair, Chief Executive Officer of Kuros Biosciences, said: 'We recorded exceptional company revenue growth of 78%, marking a pivotal phase of scale and impact for Kuros. An outstanding accomplishment is that the group has for the first time ever recorded an operating profit. With FDA clearance and U.S. launch of MagnetOs MIS, accelerating growth in extremities, and entry into new international markets, we continue to deliver with innovation, precision, and purpose. The strategic alliance with Medtronic is expanding our reach across U.S. spine markets, while our new Atlanta headquarters will enable domestic production and an immersive educational experience for surgeons, partners, and investors. Backed by strong financial performance, an experienced and diverse board, and momentum across all segments, we are well-positioned to sustain growth and create long-term value for patients, providers, and shareholders globally.' Commercial, Operational & Regulatory Highlights Medtronic U.S. Spine Partnership Gains Traction – In January 2025, Kuros finalized a five-year exclusive strategic sales agent agreement with the Medtronic spinal division for MagnetOs in mutually agreed upon U.S. sales territories. The partnership, which evolved from a successful pilot, is accelerating commercial access and hospital entry across key geographies, serving as a major force multiplier for Kuros' U.S. growth. FDA Clearance & First Cases with MagnetOs MIS Delivery System – Kuros has received FDA 510(k) clearance for its MagnetOs MIS Delivery System, a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine procedures. The system enables three times faster graft placement compared to traditional funnel-based methods, combining precise delivery with compelling Level I clinical data.1,2 Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. 'MagnetOs MIS delivered smooth, precise graft placement in a typically challenging MIS TLIF case – no preparation, no thawing, just immediate delivery and efficiency. It pairs streamlined handling with compelling clinical data, making it a meaningful advancement for surgeons who value both efficiency and biologically robust healing,' said Dr. Park. Continued Momentum in Extremities Market – With an established team dedicated to the extremities segment, Kuros is laying the groundwork for long-term success. Early progress has been promising, and the team continues to focus on targeted surgeon and distributor engagement, training, and brand awareness through an omnichannel strategy that includes key scientific meetings and driving social media presence. Global Expansion Accelerates – Following recent approval of MagnetOs Granules, ANVISA has now approved MagnetOs Putty for use in Brazil, further expanding Kuros' commercial presence in the growing South American spine market and building on recent global clearances in Lebanon and beyond. First Capital Markets Day Successfully Completed – In May 2025, Kuros hosted its inaugural Capital Markets Day in Zurich, welcoming over 130 attendees in-person and online. The event showcased the company's scientific leadership, global commercial strategy, and clinically proven differentiated approach to bone healing – featuring insights from a leading U.S. foot and ankle surgeon on how bone graft choice directly impacts patient outcomes and day-to-day quality of life. In addition, the Group presented the progress made in transforming its business from a functional, structural and digital perspective. New U.S. Headquarters and Production Facility Construction Underway – As part of its U.S. operational expansion strategy, Kuros has secured a location in Atlanta for a new office and manufacturing facility. The site is expected to support diversified manufacturing and enable Kuros to scale operations and engagement in line with accelerating demand for MagnetOs, with an immersive experience for surgeons, partners, and investors—highlighting the science, innovation, and clinical impact of MagnetOs in an engaging environment. Net operating costs Cost of goods sold amounted to USD 7.1 million in H1 2025 (H1 2024: USD 3.9 million) of which USD 0.9 million (H1 2024: USD 0.9 million) relate to the amortization of capitalized R&D. Net operating costs from continuing operations amounted to USD 52.8 million in H1 2025, compared to USD 32.0 million in the prior year period. Sales and marketing costs increased from USD 20.7 million in H1 2024 to USD 37.4 million in H1 2025, primarily driven by an expanded sales force and higher sales and distribution expenses, in line with the Group's continued commercial expansion. The increase also reflects the initial investments to penetrate the extremities and international markets, supporting future revenue growth and a broader market reach. Research and development costs of continuing operations increased from USD 3.6 million in H1 2024 to USD 4.3 million in H1 2025. This is primarily driven by increased R&D activities, clinical trial expenditures, and higher personnel expenses due to an increase in headcount, reflecting the Group's ongoing commitment to innovation to support long-term growth. General and administrative costs increased from USD 7.8 million in H1 2024 to USD 11.1 million in H1 2025. The increase was mainly driven by the scaling up of back-office functions and building the digital infrastructure to support business growth. Operating profit/ (loss) and group net result The operating profit from continuing operations amounted to USD 3.5 million (H1 2024: operating loss from continuing operations of USD (0.2) million). After accounting for the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million). Financial position and other assets Cash and cash equivalents amounted to USD 18.4 million as of H1 2025 (December 31, 2024: USD 19.8 million). The decrease in cash balance compared to year-end 2024 is mainly attributable to ongoing investments in growth initiatives and working capital to support rising demand. Funds available (including trade and other receivables) for financing the operations of Kuros amounted to USD 45.3 million as of H1 2025. This is an increase of USD 7.8 million from USD 37.5 million as of December 31, 2024. As of H1 2025, total intangible assets amounted to USD 17.6 million (2024: USD 16.4 million) and goodwill amounted to USD 24.2 million (2024: USD 21.3 million). Outlook Kuros expects MagnetOs to continue its strong growth trajectory in the spine and extremity segments, gaining further market share in the U.S., Europe and the rest of the world, and launching in additional countries. The company remains sufficiently financed to support its planned organic growth path and continues to expect robust sales growth of at least 60% in 2025. Based on the solid performance in the first half of the year, Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Key figures H1 2025 H1 2024Restated In TUSD, IFRS Revenue from product sales 63,480 35,684 Cost of goods sold (7,148) (3,896) Gross profit 56,332 31,788 Sales and marketing costs (37,394) (20,723) Research and development costs (4,305) (3,610) General and administrative costs (11,136) (7,826) Other income 6 126 Net operating costs (52,829) (32,033) Operating profit/ (loss) 3,503 (245) Net finance result (3,366) 1,857 Profit before tax 137 1,612 Income taxes (2,173) (1,466) Net (loss)/ profit from continuing operations (2,036) 146 Profit/ (loss) from discontinued operation, net of tax 23 (382) Net loss (2,013) (236) Net loss per share from continuing operations (in USD) (0.05) 0.00 Net loss per share (in USD) (0.05) (0.01) June 30, 2025 Dec 31, 2024Restated Cash and cash equivalents 18,442 19,762 Trade and other receivables 26,886 17,698 Half Year Report 2025The Kuros Biosciences Half Year Report 2025 can be downloaded via the following link on our website: Kuros Biosciences Interim Report 2025 Half Year Results 2025 – WebcastKuros will host a virtual webcast to discuss H1 2025 financial results on August 14, 2025, at 3:00pm CET. Investors can join the webcast via the following link: Investor Webcast RegistrationThe respective presentation can be downloaded via the following link:Kuros Biosciences WebCast H1 2025 Upcoming EventsOctober 16, 2025 – Trading Update Q3 2025 For further information, please contact:Kuros Biosciences AG Alexandre Müller Daniel Geiger Investor Relations Chief Financial Officer Tel +41 43 268 32 31 Tel +41 44 733 47 41 IR@ Growing bone with MagnetOsTM gives surgeons confidence where it matters most – delivering predictable fusion outcomes.2 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate (79% vs. 47%) of autograft in posterolateral fusions (PLFs).2 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic.**†2,3 MagnetOs grows bone on its own thanks to NeedleGripTM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors.‡§4-9 Ready-to-use, easy to mold, and reliably staying put10, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶6-9 Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. * Adjusted EBITDA excludes recurring and one-time share-based compensation and the relevant social security charges** 19 of initial 100 patients were active smokers.† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.2‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit § MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space. Data on file. MagnetOs MIS. Stempels, et al. Spine. 2024;49(19):1323-1331. van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024. van Dijk, et al. eCM. 2021;41:756-73. van Dijk, et al. J Immunol Regen Med. 2023;19:100070. Instructions for Use (IFU) MagnetOs Granules. Instructions for Use (IFU) MagnetOs Putty. Instructions for Use (IFU) MagnetOs Easypack Putty. Instructions for Use (IFU) MagnetOs Flex Matrix. Data on file. MagnetOs Putty and MagnetOs Easypack Putty. Attachment Kuros Biosciences Press Release H1 2025 Results

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store